25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

IRX (Inhalerx) Stock Analysis
Buy, Hold or Sell?

Let's analyze Inhalerx together

I guess you are interested in Inhalerx Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Inhalerx’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Inhalerx’s Price Targets

I'm going to help you getting a better view of Inhalerx Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Inhalerx Ltd

I send you an email if I find something interesting about Inhalerx Ltd.

1. Quick Overview

1.1. Quick analysis of Inhalerx (30 sec.)










1.2. What can you expect buying and holding a share of Inhalerx? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.00
Expected worth in 1 year
A$-0.01
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
A$0.00
Return On Investment
-11.5%

For what price can you sell your share?

Current Price per Share
A$0.03
Expected price per share
A$0.033 - A$0.039
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Inhalerx (5 min.)




Live pricePrice per Share (EOD)
A$0.03
Intrinsic Value Per Share
A$0.15 - A$0.18
Total Value Per Share
A$0.14 - A$0.18

2.2. Growth of Inhalerx (5 min.)




Is Inhalerx growing?

Current yearPrevious yearGrowGrow %
How rich?-$573.7k$200.6k-$519.3k-163.0%

How much money is Inhalerx making?

Current yearPrevious yearGrowGrow %
Making money-$341.6k-$185.6k-$156k-45.7%
Net Profit Margin-202.7%-305.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Inhalerx (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Inhalerx?

Welcome investor! Inhalerx's management wants to use your money to grow the business. In return you get a share of Inhalerx.

First you should know what it really means to hold a share of Inhalerx. And how you can make/lose money.

Speculation

The Price per Share of Inhalerx is A$0.033. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Inhalerx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Inhalerx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.00. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Inhalerx.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-7.8%0.00-4.5%0.00-2.6%0.00-4.7%0.00-4.1%0.00-4.9%
Usd Book Value Change Per Share0.000.0%0.00-1.9%0.00-1.6%0.00-2.0%0.00-0.6%0.00-0.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.00-1.9%0.00-1.6%0.00-2.0%0.00-0.6%0.00-0.2%
Usd Price Per Share0.02-0.02-0.02-0.03-0.04-0.05-
Price to Earnings Ratio-2.42--4.35--83.74--31.00--24.43--16.98-
Price-to-Total Gains Ratio3.97--7,016.66--2,270.04--1,574.65--1,029.42-
Price to Book Ratio-9.44--51.38--72.71--37.72--19.04--5.84-
Price-to-Total Gains Ratio3.97--7,016.66--2,270.04--1,574.65--1,029.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0215853
Number of shares46327
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (46327 shares)-28.68-9.44
Gains per Year (46327 shares)-114.72-37.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-115-1250-38-48
20-229-2400-76-86
30-344-3550-113-124
40-459-4700-151-162
50-574-5850-189-200
60-688-7000-227-238
70-803-8150-264-276
80-918-9300-302-314
90-1032-10450-340-352
100-1147-11600-378-390

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.036.00.00.0%0.036.00.00.0%
Book Value Change Per Share1.02.01.025.0%4.05.03.033.3%6.07.07.030.0%9.013.014.025.0%9.013.014.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.036.00.0%0.00.036.00.0%
Total Gains per Share1.02.01.025.0%4.05.03.033.3%6.07.07.030.0%9.013.014.025.0%9.013.014.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Inhalerx Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share----0.0010%-0.0010%-0.0010%0.0000%0.0000%
Book Value Per Share---0.004-0.002-45%0.001-386%0.002-338%0.005-179%0.008-152%
Current Ratio--0.6980.786-11%1.325-47%2.195-68%4.124-83%5.091-86%
Debt To Asset Ratio--1.6111.378+17%0.834+93%0.832+94%0.569+183%0.406+297%
Debt To Equity Ratio----0%0.685-100%0.378-100%0.315-100%0.304-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--6450058.2446311660.805+2%7761312.822-17%8922153.610-28%13741483.798-53%18038516.274-64%
Eps---0.004-0.002-43%-0.001-67%-0.002-40%-0.002-47%-0.002-36%
Ev To Sales Ratio--2.8948.078-64%15.559-81%50.029-94%539.130-99%584.475-100%
Free Cash Flow Per Share--0.0000.000+357%-0.001+478%-0.002+1129%-0.002+1221%-0.003+1514%
Free Cash Flow To Equity Per Share--0.0010.000+378%0.000+125%-0.001+161%0.001+100%0.000+6422%
Gross Profit Margin--1.0901.105-1%1.973-45%1.385-21%1.311-17%1.298-16%
Intrinsic Value_10Y_max--0.181----------
Intrinsic Value_10Y_min--0.147----------
Intrinsic Value_1Y_max---0.004----------
Intrinsic Value_1Y_min---0.004----------
Intrinsic Value_3Y_max--0.006----------
Intrinsic Value_3Y_min--0.005----------
Intrinsic Value_5Y_max--0.035----------
Intrinsic Value_5Y_min--0.031----------
Market Cap7192288.554-15%8282029.2447518371.555+10%8009594.072+3%9099055.026-9%13028771.848-36%15781773.592-48%
Net Profit Margin---1.533-2.027+32%-3.050+99%-8.946+483%-48.773+3081%-175.774+11362%
Operating Margin----0%-3.6310%-8.6210%-48.5610%-87.6160%
Operating Ratio--2.3563.294-28%3.632-35%11.862-80%50.789-95%135.939-98%
Pb Ratio-8.200+13%-9.442-51.383+444%-72.715+670%-37.719+299%-19.044+102%-5.843-38%
Pe Ratio-2.105+13%-2.424-4.351+80%-83.740+3355%-31.001+1179%-24.431+908%-16.982+601%
Price Per Share0.033-15%0.0380.033+15%0.037+3%0.041-8%0.059-36%0.072-47%
Price To Free Cash Flow Ratio46.216-15%53.21827.007+97%-51.176+196%-9.395+118%-10.232+119%-8.924+117%
Quick Ratio--0.4910.451+9%0.932-47%1.790-73%3.763-87%4.799-90%
Return On Assets---0.595-0.516-13%-0.480-19%-0.546-8%-0.406-32%-0.447-25%
Return On Equity----0%-0.0110%-0.3420%-0.3020%-0.5030%
Total Gains Per Share----0.0010%-0.0010%-0.0010%0.0000%0.0000%
Usd Book Value---573720.267-318689.457-44%200687.855-386%240561.791-338%726126.712-179%1104078.756-152%
Usd Book Value Change Per Share----0.0010%-0.0010%-0.0010%0.0000%0.0000%
Usd Book Value Per Share---0.003-0.001-45%0.001-386%0.001-338%0.003-179%0.005-152%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--4218983.0974128457.333+2%5076674.717-17%5835980.676-28%8988304.553-53%11798993.495-64%
Usd Eps---0.003-0.001-43%-0.001-67%-0.002-40%-0.001-47%-0.002-36%
Usd Free Cash Flow--25448.415-71982.070+383%-96252.287+478%-263962.382+1137%-286560.818+1226%-360580.656+1517%
Usd Free Cash Flow Per Share--0.0000.000+357%0.000+478%-0.001+1129%-0.001+1221%-0.002+1514%
Usd Free Cash Flow To Equity Per Share--0.0010.000+378%0.000+125%-0.001+161%0.000+100%0.000+6422%
Usd Market Cap4704475.943-15%5417275.3294917766.834+10%5239075.482+3%5951691.893-9%8522119.666-36%10322858.107-48%
Usd Price Per Share0.022-15%0.0250.022+15%0.024+3%0.027-8%0.039-36%0.047-47%
Usd Profit---558818.561-341647.223-39%-185636.523-67%-373857.723-33%-348539.115-38%-394505.879-29%
Usd Revenue--364412.192189073.001+93%217620.051+67%173423.495+110%113617.334+221%87813.961+315%
Usd Total Gains Per Share----0.0010%-0.0010%-0.0010%0.0000%0.0000%
 EOD+2 -5MRQTTM+14 -15YOY+12 -183Y+10 -205Y+10 -2010Y+11 -19

3.3 Fundamental Score

Let's check the fundamental score of Inhalerx Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.105
Price to Book Ratio (EOD)Between0-1-8.200
Net Profit Margin (MRQ)Greater than0-1.533
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.491
Current Ratio (MRQ)Greater than10.698
Debt to Asset Ratio (MRQ)Less than11.611
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.595
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Inhalerx Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.033
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Inhalerx Ltd

InhaleRx Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as Lifespot Health Ltd and changed its name to InhaleRx Limited in October 2021. InhaleRx Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-10-25 10:32:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Inhalerx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -153.3%Β means thatΒ $-1.53 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Inhalerx Ltd:

  • The MRQ is -153.3%. The company is making a huge loss. -2
  • The TTM is -202.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-153.3%TTM-202.7%+49.3%
TTM-202.7%YOY-305.0%+102.4%
TTM-202.7%5Y-4,877.3%+4,674.6%
5Y-4,877.3%10Y-17,577.4%+12,700.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-153.3%-78.6%-74.7%
TTM-202.7%-165.8%-36.9%
YOY-305.0%-186.4%-118.6%
3Y-894.6%-262.3%-632.3%
5Y-4,877.3%-338.6%-4,538.7%
10Y-17,577.4%-470.4%-17,107.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Inhalerx is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • -59.5% Return on Assets means thatΒ Inhalerx generatedΒ $-0.59 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Inhalerx Ltd:

  • The MRQ is -59.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -51.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-59.5%TTM-51.6%-7.9%
TTM-51.6%YOY-48.0%-3.6%
TTM-51.6%5Y-40.6%-11.0%
5Y-40.6%10Y-44.7%+4.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-59.5%-11.9%-47.6%
TTM-51.6%-11.5%-40.1%
YOY-48.0%-11.1%-36.9%
3Y-54.6%-12.0%-42.6%
5Y-40.6%-11.7%-28.9%
10Y-44.7%-13.8%-30.9%
4.3.1.3. Return on Equity

Shows how efficient Inhalerx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Inhalerx generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Inhalerx Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-1.1%+1.1%
TTM-5Y-30.2%+30.2%
5Y-30.2%10Y-50.3%+20.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.0%+14.0%
TTM--14.7%+14.7%
YOY-1.1%-15.0%+13.9%
3Y-34.2%-16.6%-17.6%
5Y-30.2%-17.0%-13.2%
10Y-50.3%-19.4%-30.9%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Inhalerx Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Inhalerx is operatingΒ .

  • Measures how much profit Inhalerx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Inhalerx Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-363.1%+363.1%
TTM-5Y-4,856.1%+4,856.1%
5Y-4,856.1%10Y-8,761.6%+3,905.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--164.9%+164.9%
TTM--268.1%+268.1%
YOY-363.1%-244.8%-118.3%
3Y-862.1%-247.4%-614.7%
5Y-4,856.1%-331.9%-4,524.2%
10Y-8,761.6%-499.7%-8,261.9%
4.3.2.2. Operating Ratio

Measures how efficient Inhalerx is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 2.36 means that the operating costs are $2.36 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Inhalerx Ltd:

  • The MRQ is 2.356. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.294. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.356TTM3.294-0.938
TTM3.294YOY3.632-0.338
TTM3.2945Y50.789-47.495
5Y50.78910Y135.939-85.150
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3561.898+0.458
TTM3.2942.730+0.564
YOY3.6322.820+0.812
3Y11.8623.559+8.303
5Y50.7894.571+46.218
10Y135.9396.270+129.669
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Inhalerx Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Inhalerx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.70Β means the company has $0.70 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Inhalerx Ltd:

  • The MRQ is 0.698. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.786. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.698TTM0.786-0.089
TTM0.786YOY1.325-0.538
TTM0.7865Y4.124-3.338
5Y4.12410Y5.091-0.967
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6983.298-2.600
TTM0.7863.586-2.800
YOY1.3254.036-2.711
3Y2.1954.408-2.213
5Y4.1245.712-1.588
10Y5.0916.080-0.989
4.4.3.2. Quick Ratio

Measures if Inhalerx is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.49Β means the company can pay off $0.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Inhalerx Ltd:

  • The MRQ is 0.491. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.451. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.491TTM0.451+0.040
TTM0.451YOY0.932-0.481
TTM0.4515Y3.763-3.312
5Y3.76310Y4.799-1.036
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4912.912-2.421
TTM0.4513.185-2.734
YOY0.9323.852-2.920
3Y1.7904.393-2.603
5Y3.7635.692-1.929
10Y4.7996.457-1.658
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Inhalerx Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of InhalerxΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Inhalerx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.61Β means that Inhalerx assets areΒ financed with 161.1% credit (debt) and the remaining percentage (100% - 161.1%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Inhalerx Ltd:

  • The MRQ is 1.611. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.378. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.611TTM1.378+0.232
TTM1.378YOY0.834+0.545
TTM1.3785Y0.569+0.810
5Y0.56910Y0.406+0.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6110.346+1.265
TTM1.3780.361+1.017
YOY0.8340.331+0.503
3Y0.8320.344+0.488
5Y0.5690.348+0.221
10Y0.4060.378+0.028
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Inhalerx is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Inhalerx Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.685-0.685
TTM-5Y0.315-0.315
5Y0.31510Y0.304+0.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.401-0.401
TTM-0.439-0.439
YOY0.6850.415+0.270
3Y0.3780.471-0.093
5Y0.3150.469-0.154
10Y0.3040.517-0.213
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Inhalerx generates.

  • Above 15 is considered overpriced butΒ always compareΒ Inhalerx to theΒ Biotechnology industry mean.
  • A PE ratio of -2.42 means the investor is paying $-2.42Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Inhalerx Ltd:

  • The EOD is -2.105. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.424. Based on the earnings, the company is expensive. -2
  • The TTM is -4.351. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.105MRQ-2.424+0.319
MRQ-2.424TTM-4.351+1.927
TTM-4.351YOY-83.740+79.389
TTM-4.3515Y-24.431+20.080
5Y-24.43110Y-16.982-7.449
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.105-2.909+0.804
MRQ-2.424-2.358-0.066
TTM-4.351-2.715-1.636
YOY-83.740-3.615-80.125
3Y-31.001-3.803-27.198
5Y-24.431-5.965-18.466
10Y-16.982-6.965-10.017
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Inhalerx Ltd:

  • The EOD is 46.216. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 53.218. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 27.007. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD46.216MRQ53.218-7.002
MRQ53.218TTM27.007+26.211
TTM27.007YOY-51.176+78.183
TTM27.0075Y-10.232+37.239
5Y-10.23210Y-8.924-1.308
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD46.216-3.570+49.786
MRQ53.218-2.941+56.159
TTM27.007-3.869+30.876
YOY-51.176-4.368-46.808
3Y-9.395-5.330-4.065
5Y-10.232-8.302-1.930
10Y-8.924-9.974+1.050
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Inhalerx is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -9.44 means the investor is paying $-9.44Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Inhalerx Ltd:

  • The EOD is -8.200. Based on the equity, the company is expensive. -2
  • The MRQ is -9.442. Based on the equity, the company is expensive. -2
  • The TTM is -51.383. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.200MRQ-9.442+1.242
MRQ-9.442TTM-51.383+41.941
TTM-51.383YOY-72.715+21.331
TTM-51.3835Y-19.044-32.340
5Y-19.04410Y-5.843-13.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.2002.426-10.626
MRQ-9.4422.064-11.506
TTM-51.3832.243-53.626
YOY-72.7152.491-75.206
3Y-37.7192.682-40.401
5Y-19.0443.805-22.849
10Y-5.8434.462-10.305
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets1,436
Total Liabilities2,313
Total Stockholder Equity-877
 As reported
Total Liabilities 2,313
Total Stockholder Equity+ -877
Total Assets = 1,436

Assets

Total Assets1,436
Total Current Assets1,436
Long-term Assets0
Total Current Assets
Cash And Cash Equivalents 481
Net Receivables 528
Other Current Assets 426
Total Current Assets  (as reported)1,436
Total Current Assets  (calculated)1,436
+/-0
Long-term Assets
Long-term Assets  (as reported)0
Long-term Assets  (calculated)0
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,058
Long-term Liabilities255
Total Stockholder Equity-877
Total Current Liabilities
Short-term Debt 82
Accounts payable 1,740
Other Current Liabilities 237
Total Current Liabilities  (as reported)2,058
Total Current Liabilities  (calculated)2,058
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)255
Long-term Liabilities  (calculated)0
+/- 255
Total Stockholder Equity
Common Stock14,527
Retained Earnings -15,233
Accumulated Other Comprehensive Income -171
Total Stockholder Equity (as reported)-877
Total Stockholder Equity (calculated)-877
+/-0
Other
Cash and Short Term Investments 481
Common Stock Shares Outstanding 213,448
Liabilities and Stockholders Equity 1,436
Net Debt -145
Net Working Capital -622
Short Long Term Debt Total 336



6.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-06-30
> Total Assets 
352
0
6,353
6,353
5,086
5,086
3,857
3,857
3,091
3,091
2,022
2,022
624
624
714
714
1,904
1,904
3,653
3,653
2,931
2,931
2,085
2,085
2,258
2,258
1,120
1,120
1,577
1,577
582
582
646
712
1,436
1,436
1,4361,4367126465825821,5771,5771,1201,1202,2582,2582,0852,0852,9312,9313,6533,6531,9041,9047147146246242,0222,0223,0913,0913,8573,8575,0865,0866,3536,3530352
   > Total Current Assets 
352
0
6,041
6,041
4,774
4,774
3,621
3,621
2,560
2,560
1,568
1,568
552
552
657
657
1,900
1,900
3,639
3,639
2,908
2,908
2,071
2,071
2,244
2,244
1,120
1,120
1,577
1,577
582
582
646
712
1,436
1,436
1,4361,4367126465825821,5771,5771,1201,1202,2442,2442,0712,0712,9082,9083,6393,6391,9001,9006576575525521,5681,5682,5602,5603,6213,6214,7744,7746,0416,0410352
       Cash And Cash Equivalents 
273
0
5,812
5,812
4,516
4,516
3,316
3,316
2,315
2,315
1,320
1,320
425
425
487
487
1,719
1,719
3,451
3,451
2,803
2,803
1,892
1,892
2,133
2,133
526
526
716
716
333
333
195
195
481
481
4814811951953333337167165265262,1332,1331,8921,8922,8032,8033,4513,4511,7191,7194874874254251,3201,3202,3152,3153,3163,3164,5164,5165,8125,8120273
       Net Receivables 
0
0
229
229
138
249
283
283
27
226
184
184
0
95
114
114
74
120
69
69
19
19
21
21
32
32
0
492
0
802
0
142
0
447
0
528
528044701420802049203232212119196969120741141149501841842262728328324913822922900
       Other Current Assets 
79
0
0
0
121
10
23
23
219
20
64
64
127
32
41
41
180
180
118
118
84
65
157
157
111
79
594
594
861
59
249
107
451
71
955
426
426955714511072495986159459479111157157658411811818018041413212764642021923231012100079
   > Long-term Assets 
0
0
312
312
312
312
236
236
531
531
454
454
72
72
57
57
4
4
14
14
23
23
14
14
14
14
0
0
0
0
0
0
0
0
0
0
00000000001414141423231414445757727245445453153123623631231231231200
       Property Plant Equipment 
0
0
45
45
54
54
42
42
96
96
84
84
0
0
0
56
0
0
10
10
10
10
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001010101000560008484969642425454454500
       Goodwill 
0
0
0
0
0
0
0
0
140
140
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000014014000000000
       Intangible Assets 
0
0
267
267
141
141
194
194
294
294
370
370
0
0
2
2
4
4
3
3
14
14
14
14
14
14
0
0
0
0
0
0
0
0
0
0
00000000001414141414143344220037037029429419419414114126726700
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000000
> Total Liabilities 
82
0
345
345
554
580
552
552
408
408
346
346
284
284
233
233
580
580
508
508
253
253
336
336
355
330
468
468
911
911
634
634
776
776
2,313
2,313
2,3132,313776776634634911911468468330355336336253253508508580580233233284284346346408408552552580554345345082
   > Total Current Liabilities 
82
0
345
345
554
554
552
552
408
408
346
346
284
284
233
233
580
580
508
508
253
253
336
336
355
330
468
468
911
911
633
633
776
776
2,058
2,058
2,0582,058776776633633911911468468330355336336253253508508580580233233284284346346408408552552554554345345082
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
-20
0
-20
0
-85
0
0
0
-25
0
0
0
0
92
92
560
560
319
319
34
34
82
82
8282343431931956056092920000-25000-850-200-200000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
560
0
0
0
34
0
0
003400056000000000000000000000000000000
       Accounts payable 
52
0
345
345
118
118
552
552
80
80
346
346
48
48
213
213
125
125
306
306
73
73
149
149
123
123
270
270
184
184
146
146
568
568
1,740
1,740
1,7401,740568568146146184184270270123123149149737330630612512521321348483463468080552552118118345345052
       Other Current Liabilities 
30
0
0
0
436
436
0
0
329
329
0
0
236
216
20
20
455
455
202
10
180
155
188
188
233
233
106
106
167
167
169
169
174
174
237
237
237237174174169169167167106106233233188188155180102024554552020216236003293290043643600030
   > Long-term Liabilities 
0
0
0
0
0
26
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
255
255
25525500000000000000000000000000002600000
> Total Stockholder Equity
270
0
5,945
5,945
4,507
4,507
3,371
3,371
2,683
2,683
1,676
1,676
340
340
481
481
1,324
1,324
3,144
3,144
2,678
2,678
1,748
1,748
1,903
1,928
652
652
665
665
-52
-52
-131
-64
-877
-877
-877-877-64-131-52-526656656526521,9281,9031,7481,7482,6782,6783,1443,1441,3241,3244814813403401,6761,6762,6832,6833,3713,3714,5074,5075,9455,9450270
   Common Stock
301
0
8,018
8,018
8,018
8,018
8,018
8,018
8,243
8,243
8,243
8,243
8,243
8,243
8,853
8,853
10,455
10,455
12,800
12,800
12,901
12,901
12,901
12,901
13,928
13,928
14,076
14,076
14,076
14,076
14,076
14,076
14,527
14,527
14,527
14,527
14,52714,52714,52714,52714,07614,07614,07614,07614,07614,07613,92813,92812,90112,90112,90112,90112,80012,80010,45510,4558,8538,8538,2438,2438,2438,2438,2438,2438,0188,0188,0188,0188,0188,0180301
   Retained Earnings -15,233-15,233-14,379-14,445-13,907-13,907-13,169-13,169-13,150-13,150-11,695-11,726-10,150-10,150-9,254-9,254-8,700-8,700-8,143-8,143-7,404-7,404-6,938-6,938-5,813-5,813-4,770-4,770-4,161-4,161-3,094-3,094-1,693-1,6930-31
   Capital Surplus 000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
-8,997
0
0
0
0
-988
-988
0
-956
0
-969
-1,002
-1,002
-299
-304
0
0
0
-331
0
0
0
0
0
0
000000-331000-304-299-1,002-1,002-9690-9560-988-9880000-8,99700000000000



6.3. Balance Sheets

Currency in AUD. All numbers in thousands.




6.4. Cash Flows

Currency in AUD. All numbers in thousands.




6.5. Income Statements

Currency in AUD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue335
Cost of Revenue-0
Gross Profit335335
 
Operating Income (+$)
Gross Profit335
Operating Expense-1,662
Operating Income-1,327-1,327
 
Operating Expense (+$)
Research Development622
Selling General Administrative825
Selling And Marketing Expenses65
Operating Expense1,6621,512
 
Net Interest Income (+$)
Interest Income4
Interest Expense-88
Other Finance Cost-0
Net Interest Income-84
 
Pretax Income (+$)
Operating Income-1,327
Net Interest Income-84
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,276-1,378
EBIT - interestExpense = -88
-1,678
-1,188
Interest Expense88
Earnings Before Interest and Taxes (EBIT)0-1,188
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-1,276
Tax Provision-0
Net Income From Continuing Ops-1,209-1,276
Net Income-1,276
Net Income Applicable To Common Shares-1,209
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses1,662
Total Other Income/Expenses Net5184
 

Technical Analysis of Inhalerx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Inhalerx. The general trend of Inhalerx is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Inhalerx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Inhalerx Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Inhalerx Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.034 < 0.035 < 0.039.

The bearish price targets are: 0.033 > 0.033 > 0.033.

Know someone who trades $IRX? Share this with them.πŸ‘‡

Inhalerx Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Inhalerx Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Inhalerx Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Inhalerx Ltd.

Inhalerx Ltd Daily Moving Average Convergence/Divergence (MACD) ChartInhalerx Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Inhalerx Ltd. The current adx is .

Inhalerx Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Inhalerx Ltd.

Inhalerx Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Inhalerx Ltd.

Inhalerx Ltd Daily Relative Strength Index (RSI) ChartInhalerx Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Inhalerx Ltd.

Inhalerx Ltd Daily Stochastic Oscillator ChartInhalerx Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Inhalerx Ltd.

Inhalerx Ltd Daily Commodity Channel Index (CCI) ChartInhalerx Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Inhalerx Ltd.

Inhalerx Ltd Daily Chande Momentum Oscillator (CMO) ChartInhalerx Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Inhalerx Ltd.

Inhalerx Ltd Daily Williams %R ChartInhalerx Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Inhalerx Ltd.

Inhalerx Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Inhalerx Ltd.

Inhalerx Ltd Daily Average True Range (ATR) ChartInhalerx Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Inhalerx Ltd.

Inhalerx Ltd Daily On-Balance Volume (OBV) ChartInhalerx Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Inhalerx Ltd.

Inhalerx Ltd Daily Money Flow Index (MFI) ChartInhalerx Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Inhalerx Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-07-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-09-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-09-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-09-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-10-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-10-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Inhalerx Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Inhalerx Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.033
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Inhalerx with someone you think should read this too:
  • Are you bullish or bearish on Inhalerx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Inhalerx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Inhalerx Ltd

I send you an email if I find something interesting about Inhalerx Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Inhalerx Ltd.

Receive notifications about Inhalerx Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.